Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Korean for Quarterly Report) covering the period from January 1, 2026 to March 31, 2026 (the 49th term). It contains detailed financial statements, tables on revenue, production, capital changes, share holdings, and other substantive interim-period data. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 75% confidence The document is a voluntary regulatory disclosure (“자율공시”) by Hana Pharm presenting its corporate value enhancement plan. It is not an annual or interim financial report, executive compensation disclosure, dividend notice, or management change announcement, nor does it convey a financing transaction. It is a standalone corporate plan filing that does not fit into any other specific category. Therefore, the correct classification is the general Regulatory Filings category (RNS).
2026-04-20 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document text is the announcement of the results of the 2026 regular Annual General Meeting (AGM) for Hana Pharm (“정기주주총회결과”). It details the approval of the financial statements, dividend resolution, election of directors and auditors, and vote counts/approval rates for each AGM agenda item. This fits exactly the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-30 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Hana Pharm. It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit), and the auditor's name. While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body (DART), which is a standard procedure for audit reporting. Given the document is a standalone report of the audit results and opinion, it fits the 'Audit Report / Information' category. FY 2025
2026-03-20 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for Hana Pharm Co., Ltd. for the fiscal year 2025. It contains detailed sections including company overview, history, capital structure, shareholder information, business operations, product details, and financial data. This document is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2025
2026-03-20 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal notification filed with the regulatory body (KRX) regarding the company's decision to hold its Annual General Meeting on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling and provides the meeting date. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.